Purpose Chemotherapy-induced nausea and vomiting (CINV) is common among cancer patients. Early identification of patients at risk for CINV may help to personalize anti-emetic therapies. To date, few studies have examined the combined contributions of patient-reported and genetic risk factors to CINV. The goal of this study was to evaluate these risk factors. Methods Prior to their first chemotherapy infusion, participants completed demographic and risk factor questionnaires and provided a blood sample to measure genetic variants in ABCB1 (rs1045642) and HTR3B (rs45460698) as well as CYP2D6 activity score. The M.D. Anderson Symptom Inventory was completed at 24 h and 5-day post-infusion to assess the severity of acute and delayed CINV, respectively. Results Participants were 88 patients (55% female, M = 60 years). A total of 23% experienced acute nausea and 55% delayed nausea. Younger age, history of pregnancy-related nausea, fewer hours slept the night prior to infusion, and variation in ABCB1 were associated with more severe acute nausea; advanced-stage cancer and receipt of highly emetogenic chemotherapy were associated with more severe delayed nausea (p values < 0.05). In multivariable analyses, ABCB1 added an additional 5% predictive value beyond the 13% variance explained by patient-reported risk factors. Conclusions The current study identified patient-reported and genetic factors that may place patients at risk for acute nausea despite receipt of guideline-consistent anti-emetic prophylaxis. Additional studies examining other genetic variants are needed, as well as the development of risk prediction models including both patient-reported and genetic risk factors.
prescribed chemotherapy regimen due to the significant impact of CINVon quality of life and activities of daily living [7, 8] . Consequently, CINV is a significant clinical problem.
CINV can be separated into acute (occurring in the first 24 h of chemotherapy) and delayed (occurring between day 2 to d ay 5) nausea and vom iting. Docum ent ed patient-reported risk factors for acute and delayed CINV include younger age, female gender, greater anxiety, history of motion sickness, history of morning sickness during pregnancy, non-habitual alcohol consumption, non-smoking status, less sleep the night before chemotherapy, and previous chemotherapy [9] [10] [11] [12] . A series of recent studies have analyzed demographic, clinical, and patient-reported risk factors to develop and validate predictive indices of acute and delayed CINV [9] [10] [11] . Each index yields a dichotomous risk score (high/low) intended to be used in routine clinical practice to tailor anti-emetic therapy [9] . Nevertheless, since these indices were developed, new research has been published suggesting that genetic variation may also predict CINV [13] [14] [15] .
Several studies have shown that variation in genes involved in transport and metabolism of anti-emetic drugs are associated with inter-individual differences in response to these agents [16, 15, [17] [18] [19] . For example, 5-hydroxytryptamine type 3 receptor antagonists (5HT 3 -RA) are one of the most commonly prescribed classes of anti-emetic drugs in oncology and HTR3 genes code for its therapeutic target [20] . Data suggest that variations in HTR3A, HTR3B, HTR3C, and HTR3D genes are associated with the efficacy of 5HT 3 -RA in cancer patients; of these, the most evidence exists for HTR3B [21, 13, 22] . Similarly, variants in a gene coding for 5HT 3 -RAs drug transporter ATP-binding cassette B1 protein (ABCB1) have been shown to be associated with acute nausea and vomiting, particularly in the first 24 h of chemotherapy [16, 14] . Additionally, as a majority of the anti-emetic drugs (including 5HT3-RA and dopamine antagonists) are metabolized by the cytochrome P 450 (CYP) D6 system in the liver; variation in CYP2D6 can result in large variations in their metabolism and may ultimately affect the overall drug response [15] . For example, CYP2D6 ultrarapid metabolizers, who have additional functional copies of alleles, tend to report greater CINV when treated with ondansetron and tropisteron [23] . Nevertheless, the abovementioned genes have never been examined in the context of patient-reported risk factors. Doing so could lead to earlier identification of patients at risk of CINV who may benefit from stronger anti-emetic prophylaxis such as netupitant-palenosetron plus dexamethasone or the addition of alprazolam, lorazepam, olanzapine, or metoclopramide to their anti-emetic regimen [24] .
The goal of the current study was to examine the independent contributions of genetic variants over and above recognized demographic, clinical, and patient-reported risk factors. In addition to the demographic, clinical, and patient-reported risk factors identified in previous research, we investigated variation in three genes previously found to be associated with CINV: HTR3B, ABCB1, and CYP2D6. We hypothesized that demographic, clinical, and patient-reported risk factors and genetic variants would demonstrate significant associations with CINV in univariate analyses. We also hypothesized that genetic variants would contribute significant variance in CINV over and above that contributed by demographic, clinical, and patient-reported risk factors.
Methods

Participants
Eligible patients were (a) ≥ 18 years of age, (b) capable of speaking and reading English or Spanish, (c) diagnosed with cancer, (d) chemotherapy naïve, (e) scheduled to receive highly or moderately emetogenic intravenous standard-dose chemotherapy as defined by the 2011 American Society of Clinical Oncology (ASCO) antiemesis guidelines [25] at Moffitt Cancer Center, and (f) able to provide informed consent. All patients who participated in the study signed an IRB-approved written informed consent document.
Procedures
Participants were recruited between April 2014 and April 2015. Potential participants were identified using the existing computerized appointment system and in consultation with the medical team. Participants were recruited prior to their first chemotherapy infusion. Following informed consent, participants were asked to complete a baseline sociodemographic questionnaire and provide a blood sample to assess genetic variants. On the morning of the first infusion, participants completed a measure of self-reported risk factors. They also completed self-report measures of nausea and vomiting at 24-h post-infusion (i.e., acute) and 5-day post-infusion (i.e., delayed). Electronic email or call reminders were sent to ensure timely completion.
Measures
Demographic and clinical characteristics
Demographic variables assessed via self-report included age, gender, race, ethnicity, education, marital status, annual household income, and history of smoking and alcohol use. Medical comorbidities were assessed at recruitment using a self-report version of the Charlson Comorbidity Index [26] . Participants were asked to list any non-prescription medications and supplements that they were taking over the study period. Clinical variables collected via medical record review included date of diagnosis, cancer type, disease stage, date of on-study chemotherapy infusions, chemotherapy regimen, prescribed anti-emetic drugs, and changes in anti-emetic regimens between the first and second infusion.
Patient-reported risk factors
Variables assessed were selected based on previous literature [9] [10] [11] [12] . They included hours of sleep the night before the first infusion, extent of the meal before the first infusion (i.e., liquids only, light meal, or snack, full meal), history of nausea and vomiting (i.e., due to pregnancy, motion sickness, and anxiety), recent surgery, expectancies regarding post-chemotherapy nausea and vomiting, and current anxiety.
Acute and Delayed Nausea and Vomiting
The MD Anderson Symptom Inventory (MDASI) [27] was used to assess the severity of patient-reported CINV. Items used in the current analyses were Byour nausea at its worstâ nd Byour vomiting at its worst^keyed to Bthe last 24 h^for acute CINV and B24 or more hours after chemotherapy^for delayed CINV. Items are evaluated on an 11-point Likert scale (0 = not present, 10 = as bad as you can imagine). Additional items asked what patients did about their CINV (e.g., ate less than usual, took anti-emetic medication, went to a hospital or urgent care facility, received intravenous fluids); these items were selected based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.3 [28] . Responses were used by research staff to rate acute and delayed nausea and vomiting according to the CTCAE.
Blood Collection and Analysis
Blood was collected in 10 ml EDTA tubes, inverted 10 times, chilled, and sent to the Moffitt Tissue Core for DNA purification. DNA was extracted using the AutoPure system (Autogen, Holliston, MA). DNA quantity and quality was assessed using the Qubit fluorometer (Thermo Fisher Scientific, Waltham, MA) and the Agilent TapeStation (Agilent Genomics, Santa Clara, CA). Samples were centrifuged and plasma aliquoted into multiple 1.2 mL cryovials and frozen at − 80°C. Genotyping was conducted by Cancer Genetics Inc. (Rutherford, NJ). Variants genotyped included rs1045642 in ABCB1, rs45460698 in HTR3B, and CYP2D6 *2, *3, *4, *5, *6, *7, *9, *10, *17, *21, *29, and *41. CYP2D6 results were used to categorize patients into phenotypes (i.e., poor, intermediate, extensive, and ultrarapid metabolizers) [29] . A continuous activity score was also assigned with higher scores indicating more rapid metabolism [30] .
Statistical analysis
Participants' demographic and clinical characteristics were summarized using descriptive statistics. Spearman correlations, chi-squares, and Kruskal-Wallis tests were used to examine univariate relationships among demographic, clinical, patient-reported and genetic variables and outcomes. Variables examined included age, gender, cancer stage, comorbidities, chemotherapy emetogenicity (i.e., highly versus moderately emetogenic), alcohol use, hours of sleep the night before the first infusion, extent of the meal before the first infusion (i.e., liquids only, light meal or snack, full meal), history of nausea and vomiting (i.e., due to pregnancy, motion sickness, and anxiety), recent surgery, expectancies (i.e., regarding post-chemotherapy nausea and vomiting), and current anxiety. Primary outcomes were patient ratings of severity of acute and delayed CINV. Secondary outcomes were CTCAE grade of acute and delayed CINV (i.e., ≥ grade 2 versus < grade 2) and change in anti-emetic regimen from the first to second infusion. Risk factors correlated with outcomes at p < 0.05 were entered as independent variables in multivariable hierarchical multiple regression analyses to determine their combined contributions. Demographic, clinical, and patient-reported risk factors were entered into the first step and genetic risk factors were entered into the second step. All statistical analyses were performed using SAS 9.4 (Cary, NC).
Results
Patient characteristics
A total of 120 eligible patients who were approached signed consent (90%). Of these, 107 (89%) completed the study, genotyping was conducted on 93 patients, and 88 patients had complete self-report and genetic data. Therefore, 88 patients were included in the current analyses. Demographic and clinical characteristics of the sample are shown in Table 1 . Patients were a mean age of 60 years (SD = 10) The majority of patients were female (55%); white (93%), non-Hispanic (97%), and had an annual household income of at least $40,000 per year (60%). Most patients were diagnosed with gastrointestinal (34%), thoracic (27%), or breast malignancies (26%); had advanced-stage disease (74%); and received highly emetogenic chemotherapy regimens (65%). Prescribed anti-emetic medications are shown in Table 2 . Nearly all participants received palonosetron (99%) and dexamethasone (98%). Additional commonly used anti-emetics included prochlorperazine (88%), ondansetron (46%), and fosaprepitant (34%). Patient-reported and genetic risk factors for CINV are summarized in Table 3 . Most participants could be characterized as CYP2D6 intermediate or extensive metabolizers, 77% of participants had at least on copy of the variant ABCB1 allele at rs1045642, and 31% had the variant deletion at rs1045642.
Rates of CINV
Mean self-reported CINV severity and CTCAE ratings are displayed in Table 4 . A total 12% of patients experienced CTCAE grade 2 or above acute nausea and 30% experienced delayed nausea. Vomiting of any CTCAE grade was experienced by 3% in the acute period and 11% in the delayed period. Anti-emetic regimen was switched in 14% of patients. In the univariate analyses examining genetic risk factors, variation in ABCB1 (rs1045642) was associated with acute nausea, with heterozygotes reporting more severe acute nausea (A/G: mean = 1.91, SD = 2.83) than individuals with homozygous wild type (G/G: mean = 0.80, SD = 2.31) and homozygous variant (A/A: mean = 0.62, SD = 1.96) genotypes (Kruskal-Wallis, p = 0.04) (see Fig. 1 ). ABCB1 variation was not associated with delayed CINV (p values > 0.05). There were no associations between variation in HTR3B (rs45460698), CYP2D6 phenotype, or CYP2D6 activity score and acute or delayed CINV (p values > 0.05).
Because only patient-reported acute nausea was associated with both patient-reported and genetic risk factors, multivariable analysis focused on this outcome. Results are shown in Table 5 . Demographic, clinical, and patient-reported risk factors accounted for 13% of variance in acute nausea (p = 0.03); ABCB1 genotype added an additional 5% of variance (p = 0.10).
Discussion
The goal of the current study was to evaluate the combined contributions of demographic, clinical, patient-reported, and genetic risk factors towards predicting acute and delayed CINV. Results show that incorporation of genetic factors to CINV risk assessment indices based on patient related factors has the potential to improve prediction. Despite the recent advances in anti-emetic therapy, CINV remains a significant cause of morbidity in cancer patients [31, 7] . Our study showed a suboptimal control of nausea post-chemotherapy despite guideline-consistent anti-emetic prescribing, with 12% patients reporting moderate to severe nausea in the acute setting and 30% in the delayed setting [25] . Nevertheless, control of vomiting was high, with 1% of patients experiencing CTACE grade 2 or above acute vomiting and 5% delayed vomiting.
Control of nausea was related to patients' sociodemographic, clinical, patient-reported, and genetic characteristics. Consistent with previous studies [9] [10] [11] [12] , we found in univariate analyses that younger age and fewer hours of sleep prior to chemotherapy was significantly related to development of acute nausea. CTCAE acute nausea grade: n (%) 0 6 0 ( 6 8 % ) Advanced-stage malignancy and receipt of highly emetogenic chemotherapy were found to be significantly related to development of delayed nausea. Univariate analyses also indicated that variation in ABCB1 at rs1045642 was significantly associated with development of acute nausea. While these findings are consistent with previous literature [16, 14] , it is not clear why heterozygotes would experience greater nausea than homozygotes. It may be that this variant is in high linkage disequilibrium with a functional variant. Despite frequent use of anti-emetic agents metabolized by CYP2D6, we did not observe an association of activity score or phenotype with CINV. Lack of a relationship may be due to the fact that majority of our participants were extensive metabolizers (94%), as a result of which our study sample was not adequately powered to evaluate the CYP2D6 phenotype as a potential CINV risk factor. Similarly, we did not observe any association between variation in the HTR3B gene and the risk of CINV, perhaps due to our relatively small sample size. Over the years, there has been development of several risk assessment indices for prediction of CINV based on patient-reported risk factors and the emetogenic potential of chemotherapeutic regimens [9, 10, 32] . In a randomized control study, Clemons et al. [33] evaluated the control of CINV in breast cancer patients and found significant improvement in both acute and delayed CINV when patients were given a tailored anti-emetic medication regimen based on an established risk-based model. We found that demographic, clinical, patient-reported, and genetic factors accounted for a combined 18% of the variance in acute nausea, with genetic factors accounting for 5%. Our data suggest that existing algorithms may be improved by including genetic information. Relatively few candidate gene studies have been conducted to date; additional, larger studies such as genome-wide association studies (GWAS) are needed to provide a more comprehensive examination of genetic risk factors for CINV. The falling cost of genotyping, in combination with CLIA-certified genotyping available to providers and consumers, suggests that genotype-based anti-emetic prescribing is likely to become increasingly practical.
Our study is one of the first to look at the combination of patient-reported and genetic risk factors to identify risk of CINV in cancer patients. Strengths of the study include a clinically important research question; longitudinal, prospective design; a sample that was heterogeneous in terms of diagnosis and stage; well-validated measures of CINV; and appropriate statistical analyses. Limitations of the study should also be noted. Our sample of 88 patients was relatively small and the incidence of some outcomes, such as vomiting, was low. Therefore, the study may have lacked statistical power to detect more subtle effects of patient-reported and genetic risk factors on CINV. Additionally, our sample was relatively homogeneous in terms of race and ethnicity; additional studies are needed to determine whether findings can be generalized to other racial and ethnic groups.
In conclusion, the current study suggests that patient-reported and genetic risk factors may improve early identification of patients at risk of CINV. Additional studies are needed to confirm our results and systematically investigate the role of additional genetic variants (i.e., GWAS) to select appropriate genetic risk factors for tailored anti-emetic prescribing in clinical practice. Future research will be targeted towards establishing additional genetic variants responsible for inter-individual variability in CINV risk, development and dissemination of risk prediction models, and evaluating the cost effectiveness of risk-based anti-emetic prescribing. Additional research should also focus on pharmacogenetics studies of anti-emetic metabolism. Improved nausea risk prediction and management would be highly impactful for the 650,000 cancer patients who receive outpatient chemotherapy in the USA each year [34] .
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